Cerebrovascular disease
Conditions
Interventions
Propofol group:Anesthesia induced propofol 1.0~1.5 mg/kg, followed by intravenous sufentanil 0.3~0.4 µg/kg and cis-atracurium 0.15 mg/kg, and the anesthesia maintenance group P group was administered
Remimazolam group:Anesthesia was induced with remimazolam 0.3 mg/kg, followed by intravenous sufentanil 0.3~0.4 µg/kg and cis-atracurium 0.15 mg/kg, anesthesia maintenance intravenous infusion of remi
Sponsors
Department of Anesthesiology, The First Affiliated Hospital of the University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Gender is not limited 2. Age >= 18 years old 3. Patients who have been clearly diagnosed with cerebrovascular intervention under general anesthesia 4. BMI 18~30kg/m^2; 5. ASA grade II. to III. 6. Mini-cog scale 1-3 points 7. Fully informed consent of the patient.
Exclusion criteria
Exclusion criteria: 1. Subjects who are undergoing other clinical trials 2. Use of opioid analgesics within 24 hours before surgery 3. History of metabolic diseases (metabolic syndrome, diabetes, etc.) 4. History of allergy to the drugs in this study 5. Severe arrhythmias (such as sinus bradycardia, atrioventricular block, etc.) 6. Severe liver and kidney function abnormalities 7. History of severe psychiatric or neurological diseases 8. Mini-cog scale 0 points 9. Other reasons are not suitable for this investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RAAS score;3D-CAM scoring;Glasgow Rating;Clock test;Postoperative recovery quality assessment scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total dosage of Remimazolam;Total amount of propofol used;Total dosage of norepinephrine use;Total usage of remifentanil;HR, BP, and SPO2 values at T1 (upon entering the room), T2 (during intubation), T3 (during surgical puncture), T4 (during surgical embolization/stent placement), T5 (while using the stapler), T6 (upon entering PACU), T7 (during extubation), and T8 (upon leaving PACU);Intraoperative fluid volume;Blood loss;Urine output;Time to response after entering the PACU (calculated from the cessation of study drug infusion);Awake time;Time to recovery of spontaneous breathing;Time of tube removal;PACU stay duration;Adverse event;PACU Medication; | — |
Countries
China
Contacts
Public ContactFang Kang
Department of Anesthesiology, The First Affiliated Hospital of the University of Science and Technology of China
Outcome results
None listed